Emergent BioSolutions Inc. announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA). This modification is for the supply of TEMBEXA (brincidofovir) oral suspension, a smallpox antiviral.
This contract follows the U.S. Food and Drug Administration’s recent approval of TEMBEXA oral suspension, which is particularly important for patients who have difficulty swallowing. The award strengthens the overall U.S. supply chain for this critical medical countermeasure.
TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. This contract reinforces Emergent's commitment to national preparedness and its role in providing solutions for public health threats.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.